In search of the perfect comorbidity measure for use with administrative claims data: does it exist?

Published: August 1, 2006
Category: Bibliography > Papers
Authors: Baldwin LM, Barlow W, Green P, Klabunde CN, Wright G
Countries: United States
Language: null
Types: Care Management
Settings: Academic

Med Care 44:745-753.

Department of Family Medicine, University of Washington, Seattle, WA, USA

BACKGROUND: Numerous measures of comorbidity have been developed for health services research with administrative claims.

OBJECTIVE: We sought to compare the performance of 4 claims-based comorbidity measures.

RESEARCH DESIGN AND SUBJECTS: We undertook a retrospective cohort study of 5777 Medicare beneficiaries ages 66 and older with stage III colon cancer reported to the Surveillance, Epidemiology, and End Results Program between January 1, 1992 and December 31, 1996.

MEASURES: Comorbidity measures included Elixhauser’s set of 30 condition indicators, Klabunde’s outpatient and inpatient indices weighted for colorectal cancer patients, Diagnostic Cost Groups, and the Adjusted Clinical Group (ACG) System. Outcomes included receipt of adjuvant chemotherapy and 2 year noncancer mortality.

RESULTS: For all measures, greater comorbidity significantly predicted lower receipt of chemotherapy and higher noncancer death. Nested logistic regression modeling suggests that using more claims sources to measure comorbidity generally improves the prediction of chemotherapy receipt and noncancer death, but depends on the measure type and outcome studied. All 4 comorbidity measures significantly improved the fit of baseline regression models for both chemotherapy receipt (baseline c-statistic 0.776; ranging from 0.779 after adding ACGs and Klabunde to 0.789 after Elixhauser) and noncancer death (baseline c-statistic 0.687; ranging from 0.717 after adding ACGs to 0.744 after Elixhauser).

CONCLUSIONS: Although some comorbidity measures demonstrate minor advantages over others, each is fairly robust in predicting both chemotherapy receipt and noncancer death. Investigators should choose among these measures based on their availability, comfort with the methodology, and outcomes of interest.

PMID: 16862036
PMCID: PMC3124350

Co-morbidity,Outcome Measures,Age,High-Impact Chronic Conditions,United States,Aged,80 and over,Cohort Studies,Colonic Neoplasms,Gender,Medicare,Retrospective Studies,SEER Program

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top